24/7 Market News Snapshot 07 October, 2025 – Klotho Neurosciences, Inc. Common Stock (NASDAQ:KLTO)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (Nasdaq:KLTO) are discussed in this article.
Klotho Neurosciences, Inc. (Nasdaq:KLTO) commenced trading today at $0.536 and experienced a significant increase of 17.5%, reaching $0.611. This upward movement was accompanied by a robust trading volume of 6.21 million shares, reflecting strong investor interest. The stock is now approaching potential resistance around the $0.60 level, with prospects for continued growth if trading volume remains high. Critical support is identified at the opening price of $0.536.

In a strategic pivot, Klotho has officially ended its Letter of Intent with Turn Biotechnologies, following a decision by the Board of Directors that the collaboration did not align with the Company’s long-term vision. This transition underscores Klotho’s commitment to enhancing its focus within the rapidly evolving longevity medicine sector, which is particularly pertinent given global aging trends, with the elderly population projected to surpass 2.1 billion by 2050.

Klotho is directing its research efforts toward the human Klotho protein, recognized for its crucial role in mitigating the aging process, and aims to develop innovative therapies targeting neurodegenerative and age-related conditions such as ALS, Alzheimer’s, and Parkinson’s diseases. This initiative comes in light of escalating healthcare costs projected to reach $47 trillion by 2030, positioning Klotho’s disease-modifying therapy pursuits as timely and strategically essential.

The Company’s proprietary technology leverages a patented formulation of the human Klotho gene, alongside advanced delivery systems for cell and gene therapies. This approach not only reaffirms Klotho’s dedication to fostering health improvements but also to enhancing value for both patients and shareholders. Comprising a team of seasoned biopharmaceutical professionals, Klotho is well-prepared to navigate the dynamic landscape of longevity medicine, with stakeholders anticipating ongoing progress updates as the company strives to redefine healthspan and lifespan outcomes for future generations.

Related news for (KLTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.